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Abstract 
 
Microneedles (MNs) have been investigated as a minimally-invasive delivery technology for a range 
of active pharmaceutical ingredients (APIs). Various formulations and methods for coating the 
surface of MNs with therapeutics have been proposed and exemplified, predominantly for hydrophilic 
drugs and particulates. The development of effective MN delivery formulations for hydrophobic drugs 
is more challenging with dosing restrictions and the use of organic solvents impacting on both the 
bioactivity and the kinetics of drug release. In this study we propose a novel formulation that is 
suitable for MN coating of hydrophobic auto-antigen peptides currently being investigated for antigen 
specific immunotherapy (ASI) of type 1 diabetes. The formulation, comprising three co-solvents 
(water, 2-methyl-2-butanol and acetic acid) and polyvinylalcohol 2000 (PVA2000) can dissolve both 
hydrophilic and hydrophobic peptide auto-antigens at relatively high, and clinically relevant, 
concentrations (25 mg/ml or 12.5 mg/ml). The drug:excipient ratio is restricted to 10:1 w/w to 
maximise dose whilst ensuring that the dry-coated payload does not significantly impact on MN skin 
penetration performance. The coating formulation and process does not adversely affect the 
biological activity of the peptide. The delivery efficiency of the coated peptide into skin is influenced 
by a number of parameters. Electropolishing the metal MN surface increases delivery efficiency from 
2.0±1.0% to 59.9±6.7%. An increased mass of peptide formulation per needle, from 0.37 µg to 2 µg 
peptide dose, resulted in a thicker coating and a 20% reduction in the efficiency of skin delivery. 
Other important performance parameters for coated MNs include the role of excipients in assisting 
dissolution from the MNs, the intrinsic hydrophobicity of the peptide and the species of skin model 
used in laboratory studies. This study therefore both exemplifies the potential of a novel formulation 
for coating hydrophobic and hydrophilic peptides onto MN devices and provides new insight into the 
factors that influence delivery efficiency from coated MNs.  Importantly, the results provide guidance 
for identifying critical attributes of the formulation, coating process and delivery device, that confer 
reproducible and effective delivery from coated MNs, and thus contribute to the requirements of the 
regulators appraising these devices.  
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1. Introduction 
Microneedles (MNs) are sharp, needle-like structures with diameters and lengths generally in the 
micron range.  These structures are used to penetrate the upper layer of the skin in a non-invasive 
and painless manner to enable intraepidermal, intradermal and transdermal delivery of 
pharmaceutical products, or extraction of biological material for bio-sensing applications. 
Documented approaches to drug delivery via MNs include (i) MN penetration of skin to enhance 
permeation of a topically applied formulation, (ii) injecting, or extracting, materials through hollow 
MN apertures, (iii) delivering materials contained within a dissolving/degradable needle substrate, or 
(iv) coating the material of interest onto the surface of the needle for subsequent delivery [1]. Of 
these approaches, coated MNs have attracted significant attention due to the simplicity of MN 
manufacture and the potential to create a device with an integrated formulation that is dry-coated, 
and thus more stable for labile biologics. Coated MNs have been used for the pre-clinical and, in 
some cases, clinical delivery of a range of materials including desmopressin [2], influenza vaccine 
[3], plasmid DNA [4], siRNA [5], lidocaine [6], parathyroid hormone [7], botulinum toxin [8], measles 
vaccine [9], insulin [10], M2e-TLR5 [11], and human growth hormone [12]. 
  
The pharmaceutical formulation and procedure for coating MNs are fundamental to the coated MN 
approach. Various coating formulations and coating devices have been developed and exemplified. 
Most commonly, aqueous coating solutions are used to create a uniform thin film of material on a 
metallic MN surface [4, 7, 13-15]. Whilst these studies have demonstrated the ability to coat 
hydrophilic drugs and particulates onto MNs, published reports of successful MN coating using 
hydrophobic materials are limited and typically describe low drug loading doses [15, 16]. Gill and 
Prausnitz, 2007 used an acetonitrile and ethanol solvent system to dissolve curcumin, as a model 
hydrophobic molecule, within polymer matrices (poly(lactic-co-glycolic acid) or polyvinylpyrrolidone 
(PVP) [15]. Ethanol has also been used as a co-solvent to prepare a Eudragit E 100 co-polymer and 
propylene glycol coating formulation that is able to accommodate minoxidil to treat hair loss [16]. In 
another study, the hydrophobic anti-inflammatory drug ketoprofen was encapsulated in a hydrogel 
mixture and delivered using coated MNs; however the delivery efficiency was not reported [17]. 
Given that more than 40% of newly developed drugs are hydrophobic [29, 30], further work is 
required to design and optimise formulations to ensure that MN delivery systems can be fully 
exploited for emerging drug entities in a diversity of therapeutic areas. 
 
As an example of an emerging therapeutic, coated MNs have recently been studied for the delivery 
of peptide auto-antigens as an antigen specific immunotherapy (ASI) for type 1 diabetes [18]. In 
contrast to conventional vaccinations, which are designed to activate the immune system, this 
therapy aims to induce tolerance as a means to treat autoimmune disease [19, 20]. MNs are well 
suited to this application as targeting skin dendritic cells with auto-antigen in a minimally invasive 
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manner is more likely to mediate a tolerogenic, rather than inflammatory, immune response. The 
challenge of formulating such materials for MN delivery into skin not only relates to dosing capacity 
but also maintaining the bioactivity of the coated peptide, which may be affected by the solvents 
used in the coating formulation and the complex processes used to coat the MNs [13, 21]. In this 
specific case it will also be important to select excipients that do not stimulate a non-specific 
inflammatory response.  
 
This study aims to develop an optimised formulation for the coating and delivery of hydrophobic 
auto-antigens from stainless steel MNs. In doing so, the study provides new and improved 
understanding of those critical parameters that influence delivery efficiency using coated MNs, such 
as the hydrophobicity of the drug cargo, the role of excipients, the impact of MN surface properties 
on coating and the influence of coating thickness on skin penetration and delivery. 
 
2. Methods 
 
2.1. Microneedle and microneedle applicator manufacture 
Stainless MNs were fabricated and electropolished as described previously [18]. Briefly, MNs were 
cut from stainless steel sheets using wire electrical discharge machining (Cardiff School of 
Engineering, Cardiff, UK). The MNs were either used without further processing or following 
electropolishing using a method adapted from that described previously [22] and used in a previous 
study [18]. A bespoke MN holder and application device was manufactured from biocompatible 
acrylate polymer (e-Shell 200; EnvisionTEC, Gladbeck, Germany) at the Cardiff School of 
Engineering using additive manufacturing. The applicator was designed to facilitate simultaneous 
insertion of three planar rows of coated MNs. 
 
2.2. Coating procedure for MNs 
To coat MNs, 0.4 µl of the required formulation (equating to 10 µg peptide from a 25 mg/ml coating 
solution) was taken up in a 10 µl ultra long pipette tip using a 2.5 µl pipette. The tip was then carefully 
removed from the pipette without disturbing the liquid cargo [5] [18]. Peptide was then deposited 
onto an individual MN by brushing the aperture of the pipette tip perpendicularly and sequentially 
over the point of each needle under a microscope. Each needle was then left to briefly air dry in 
ambient conditions, leaving peptide residue on the needle surface. This was repeated for the 
required number of needles until the entire coating formulation had been extracted from the pipette 
tip and coated onto the MN surfaces.  
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2.3. Selecting solvents and excipients for coating peptides 
Three peptides, which have relevance to type 1 diabetes in the non obese diabetic (NOD) mouse 
model of type 1 diabetes, with different hydrophobicities were used in the study: WE14 
(WSRMDQLAKELTAE), a peptide of chromogranin A, m31 (YVRPLWVRME), a mimotope that 
stimulates highly diabetogenic CD4 T lymphocytes in the NOD mouse [23], and pro-insulin B9-23 
(SHLVEALYLVCGERG) (GL Biochem, Shanghai, China). The solubility of these peptides was tested 
in water, acetic acid, tert-butanol and tert-amyl alcohol (Sigma-Aldrich, Gillingham, UK). After 
determining the best combination of solvents for all three peptides, 10 µg of peptide was further 
formulated with 1 µg of the following excipients to improve the MN coating efficiency and assist 
dissolution in the skin: poly vinyl alcohol MW2000 (PVA 2000), polyethylene glycol MW1450 (PEG 
1450), pluronic 127 (PF127), pluronic 68 (PF68) or 2-hydroxypropyl-β-cyclodextrin (2HPβCD) 
(Sigma-Aldrich, Gillingham, UK).  
 
2.4. Determining the solubility of peptides in a coating formulation 
Peptides were prepared in a coating formulation at a concentration of 12.5 or 25 mg/ml to evaluate 
solubility within the solvent system. To do this, the peptide solution was centrifuged at 1000g for 10 
minutes. The clarity of the solution was then inspected against a white light board and compared to 
de-ionised water and a PVA solution (2.5 and 1.25 mg/ml).  
 
2.5. Evaluating the effect of MN coating formulation on m31 bioactivity 
BDC-2.5-TCR-Tg.NOD mice were bred and maintained in a specific pathogen-free environment 
(Joint Biological Services Unit, Cardiff University, Cardiff, UK). All experimental procedures were 
carried out in accordance with UK Home Office project license regulations and following approval by 
the Ethical Review Committee at Cardiff University. 
 
Mice were sacrificed in a sealed chamber filled with CO2. The spleen was removed, dissociated 
using a glass homogenizer and cells were filtered through a 70 µm cell strainer into a 50 ml Falcon 
tube. Cells were then pelleted at 400g for 5 minutes, lysed with 900 µl of de-ionised water and 
immediately neutralized with 100 µl of x10 PBS. Recovered splenocytes were then filtered for a 
second time through a 70 µm cell strainer and resuspended in RPMI 1640 media supplemented with 
5% FCS, 2 mM L-glutamine, 50 µM 2-mercaptoethanol and 1 U/ml penicillin/streptomycin (complete 
media) and finally kept on ice prior to use. 
 
A coating formulation of m31 peptide was prepared (the finalised coating formulations for each of 
the peptides are shown in Table 4 in the Results section) and MNs were coated with 0.4 µl of coating 
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formulation. In order to evaluate whether the coating formulation and process influenced peptide 
bioactivity, m31 peptide (lyophilised powder) or m31 peptide recovered following MN coating was 
dissolved to a concentration of 0.2, 2 or 20 ng/ml in RPMI 1640 media supplemented with complete 
media. Splenocytes (300,000/well) were cultured in 96-well round bottom plates together with 100 
µl of complete media, to which 100 µl of m31 solution was added to give a final concentration of 0.1, 
1 or 10ng/ml respectively. The plates were incubated at 37°C with 5% CO2 for 3 days. IFNγ 
concentration in the supernatant was then analysed using an IFNγ ELISA (Mouse IFN gamma ELISA 
Ready-SET-Go kit, eBioscience, Altrincham, UK). In order to detect IFNγ, purified Rat Anti-mouse 
IFNγ antibody was used as the primary antibody and biotin Rat Anti-Mouse IFNγ as the detection 
antibody. To detect the secondary antibody, horseradish peroxidase (HRP) was added and the 
colour developed using 3,3,5,5-Tetramethylbenzidine (TMB) substrate solution. Once conversion 
had taken place, the reaction was stopped by adding H2SO4 solution. Data was then acquired using 
a Multiwave plate reader (Thermo Scientific, Loughborough, UK) set at 450nm to obtain the OD 
(optical density) value. 
 
2.6. Modifying the coating thickness 
To characterise coating thickness, 1µg PVA 2000 and 10 µg WE14-5TAMRA were coated onto 5, 
15 or 30 electropolished needles, i.e. the material was distributed over different numbers of MNs to 
vary the coating thickness per individual MN. The total mass coated onto MNs was 11µg, therefore 
the average mass over 5, 15 and 30 needles was considered to be 2.2µg/needle, 0.73µg/needle 
and 0.37µg/needle respectively.  
 
2.6.1. Imaging MNs using Scanning Electron Microscopy (SEM) and 3D optical profiling 
For SEM characterisation of MNs, both uncoated and coated, the MNs were mounted on 32 x 10 
mm aluminium specimen stubs (Agar Scientific, Stansted, UK) using a small piece of a 12 mm 
adhesive carbon tab (Agar Scientific, Stansted, UK). Leit-C Conducting Carbon Cement (Agar 
Scientific, Stansted, UK) was used to secure the specimen. Mounted samples were then placed in 
an EMscope sputter coater under a low-pressure argon atmosphere and coated with gold (Agar 
Scientific, Stansted, UK) to improve surface conductivity and increase generation of secondary 
electrons, thereby improving signal/noise ratio. Samples were observed using a JEOL JSM-840A 
scanning electron microscope (JEOL, Tokyo, Japan) operating at 5kV with image capture using a 
SIS ADDAII Image Grabber with analysis software (Soft Imaging System GmbH, Munster, 
Germany). The coating thickness was further imaged using a Zeta 3D optical profiler (Zeta 
Instruments, San Jose, USA).  The thickness of the coating was analysed in two ways using the 
optical profiler software: (i) the longitudinal coating thickness along the microneedle shaft, i.e. from 
the tip to the centre of the needle base and (ii) the latitudinal coating thickness at 10 different 
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positions across the width of the MN; 10 measurements at 10 µm intervals from 30 µm from the 
needle tip to 120 µm from the needle tip.  
 
2.7. Skin delivery using coated MNs  
The delivery efficiency of coated MNs was tested in both human and mouse skin. All human skin 
samples were obtained from female patients undergoing mastectomy or breast reduction surgery 
with informed patient consent and local ethical committee approval (South East Wales Ethics 
Committee Ref. 08/WSE03/55). Excised skin was transported from surgery to the laboratory and 
stored at -20˚C. Before experimentation, frozen skin was defrosted at room temperature in PBS and 
the subcutaneous fat was removed by blunt dissection. Skin was then stretched to approximately its 
normal tension on a cork dissection board. MNs coated with either WE14-5TAMRA or m31-5TAMRA 
were firmly pressed into human skin explants and held in place for 10 minutes before removal and 
subsequent analysis of the tissue and the MNs. To apply MNs in vivo, an NOD mouse was shaved 
near the neck area using clippers.  MN arrays were then applied to the skin for 10 minutes, with the 
mouse under general anaesthetic. 
 
2.8. Quantifying delivery efficiency of Peptide-5-TAMRA using UV-vis absorbance 
The delivery efficiency of 5-TAMRA conjugated peptides was inferred by determining the mean 
loading dose that was achieved on peptide-coated MNs and subtracting the mass of peptide that 
remained on individual MNs after skin insertion. Quantification was achieved using UV-vis 
spectrometry (NanoVue Plus Spectrophotometer, GE Healthcare Life Sciences, Little Chalfont, UK), 
After skin insertion, MNs were immersed in 100 µl of 10 %v/v acetic acid in a sealed container and 
maintained at 2-8°C for 15 minutes. The absorbance of peptide-5TAMRA in the acetic acid solution 
was then measured at 559 nm using a NanoVue™ spectrophotometer (GE Healthcare Life 
Sciences, Little Chalfont, UK) and the concentration of the residual peptide on the MN calculated 
using a standard calibration curve. The peptide delivery efficiency was then calculated using the 
equation: 
Delivery efficiency (DE) = (Average mass of MN coated peptide - Coated peptide mass after skin 
insertion) / Average mass of MN coated peptide x 100% 
 
2.9. Peptide-5-TAMRA distribution in human skin explants 
Following treatment, human skin was immersed in optical cutting temperature embedding matrix at 
room temperature and then snap frozen using a mixture of methanol and dry ice. Sections (10 µm 
thickness) were obtained using a Cryostat FSE (Thermo Scientific, Loughborough, UK) with the 
chamber temperature and the sample temperature set at -20˚C.  Peptide-5-TAMRA distribution 
within skin sections was visualised using a fluorescence microscope (Leica DM IRB Microscope, 
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Leica Microsystems, Milton Keynes, UK) and images processed using ImageJ software (Rasband, 
W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 
1997-2016). 
 
3. Results:  
 
3.1 Development of a MN coating formulation suitable for hydrophobic peptides 
 
3.1.1 Selection of solvents  
The amino acid sequences and some physicochemical properties of the peptides used in this study 
are listed in Table 1. The solubility of these peptides in water is in the order WE14>m31>pro-insulin 
B9-23. Initial attempts to dissolve these peptides involved protonation of water using acetic acid. The 
pH of acetic acid solutions at concentrations of 1.9, 2.2 and 2.6 mol/L is 2.24, 2.21 and 2.17 
respectively. Whilst all of these acetic acid solutions were able to dissolve WE14 at concentrations 
ranging from 10 to 25 mg/ml, neither m31 nor pro-insulin B9-23 peptides were soluble in acetic acid 
solution with concentrations above 10 mg/ml. 
 
Table 1. Peptide properties. Peptide properties were generated using the genscript online resource, available 
at  https://www.genscript.com/ssl-bin/site2/peptide_calculation.cgi    
Peptide  Sequence  Charge 
Isoelectric 
point  pH 
Overall % of hydrophobic and 
hydrophilic amino acids 
m31 
YVRPLWVR
ME  1  9.3  Basic 
Hydrophobic: 60% 
Hydrophilic: 30% 
Neutral: 10% 
WE14 
WSRMDQLA
KELTAE  -1  4.43  Acidic 
Hydrophobic: 43% 
Hydrophilic: 36% 
Neutral: 21% 
Pro-insulin 
B9-23 
SHLVEALYL
VCGERG  0  5.48  Neutral 
Hydrophobic: 40% 
Hydrophilic: 27% 
Neutral: 33% 
 
 
Alcohols were thereafter investigated as potential co-solvents. Tert-butanol and tert-amyl alcohol 
were selected as candidate co-solvents due to their relatively low vapour pressure (to prevent 
evaporation during coating resulting in changes to formulation concentration), aqueous miscibility 
(with the acetic acid solution) and melting point (for frozen storage of the coating formulation). Table 
2. lists some key physical properties of these two alcohols (tert-butanol and tert-amyl alcohol) 
compared to water. Tert-amyl alcohol, containing an additional methyl group to tert-butanol, has a 
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lower solubility in water, lower melting point and lower vapour pressure (Table 2). Preliminary studies 
indicated that whilst tert-butanol was not able to dissolve m31 and pro-insulin B9-23 at a high peptide 
concentration (≥10mg/ml), tert-amyl alcohol dissolved these peptides at this concentration. Tert-amyl 
alcohol was therefore identified as an appropriate solvent for the development of coating 
formulations for hydrophobic peptides, whilst water or acetic acid was sufficient for the more 
hydrophilic WE14 peptide. Tert-amyl alcohol was miscible in 1.7-3.5 mol/L acetic acid/water mixtures 
at a volume ratio of 1:5 v:v, without visual observation of phase separation.    
 
Table 2. Solvent physical properties.  The physical properties of acetic acid, tert-butanol, tert-amyl alcohol 
and water. All the data were cited from http://www.chemspider.com/ 
Compound  Molecular 
weight g/mol 
Miscibility 
in water g/l 
Melting 
point ˚C 
Boiling 
point ˚C 
Vapour 
pressure kPa 
(at 20˚C) 
Acetic acid  60.05  Miscible  16 to 17  118 to 119  1.5 
Tert-butanol  74.12  Miscible 
 
25  82 to 83  4.1 
 
Tert-amyl alcohol  88.15  120  -9.1  101 to 103  1.6 
Water  18  -  0  100  2.3 
 
3.1.2 Selection of additional excipients 
A range of additional excipients was explored to i) assist dissolution of the coated peptide from the 
MN surface following insertion into skin, and ii) confer stability to the coating formulation. A previous 
Phase I clinical study has demonstrated the safety profile of a dose of 10µg pro-insulin C19-A3 
peptide [24], and therefore 10µg of auto-antigenic peptide was selected as an appropriate dose to 
coat onto each MN array. Five excipients, listed in Table 3, were tested individually to improve 
coating efficiency (peptide alone was not able to coat the needle with the current coating method). 
In order to minimise the reduction in drug coating capacity, 1µg of each excipient was used to provide 
a 1:10 w/w excipient:drug ratio.  
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Table 3. Excipients tested as components in the coating formulation to improve coating efficiency.  
Excipients  Function  Properties 
PVA (MW 2000)  Dispersant  Polymer 
PEG (MW 1450)  Dispersant  Polymer 
PF127  Nonionic Surfactant (high molecular weight)  Thermogel 
PF68  Nonionic Surfactant (low molecular weight)  Thermogel 
2HPβCD  Form inclusion complex  Sugar ring 
 
The excipients listed in Table 3 were added to the acetic acid/tert-amyl alcohol/water ternary 
solvent system using the same excipient to peptide ratio: 1:10 w:w. Only m31 peptide was used in 
these studies based upon its intermediary hydrophobicity.  
 
The delivery capabilities of these excipient formulations were then examined in human skin. 
Electropolished MN devices (30 needles) delivered up to 70% of the coated peptide dose from 
coated MN formulations (Fig.1). Formulations containing 2HPβCD or PVA excipients enabled more 
effective m31-5TAMRA release into the skin than PEG, PF127 and PF68. Downstream concerns 
about an increase in the peptide dissociation rate and the potential stimulation of a non-specific 
immune response by 2HPβCD resulted in the selection of PVA 2000 as the coating excipient of 
choice. 
 
Fig.1.  Effect of excipient selection on peptide delivery efficiency.  Excipient effect on delivery efficiency 
of m31-5TAMRA using three arrays (30 needles) of electropolished 500µm MNs.  MNs were coated with 10µg 
of m31-5TAMRA and applied to human skin explants for 10 minutes before analysing the delivery efficiency. 
N=3. Mean±SD. One-way ANOVA with Tukey’s post test. *p<0.05, **p<0.01.  
 
PF68 PF127 PEG PVA bCD 
0
20
40
60
80
100
D
e
liv
e
ry
 e
ff
ic
ie
n
c
y
 µ
g
/µ
g
 %
*
*
*
**
**
Cyclodextrin
 11 
Table 4 summarises the composition of finalised formulations used to coat 10µg of the peptide in 
subsequent experiments. 
 
Table 4. Coating formulation composition for each peptide. The formulation was tested for its ability to 
dissolve 1mg of each peptide. The range of excipients tested is listed in Table 3.  
Peptide 
Tert-amyl 
alcohol 
(v/v%) 
Acetic acid 
Mol/L 
(v/v%) 
Water 
(v/v%) 
Peptide 
Conc. 
(mg/ml) 
PVA 
 Conc. 
(mg/ml) 
Volume to coat 
10µg peptide 
(µl) 
m31  20 
1.9 
(11%)  69  25  2.5  0.4 
WE14  - 
2.6 
(15%)  85  25  2.5  0.4 
proinsulin 
B9-23  31.25 
2.2 
(12.5%)  56.25  12.5  1.25  0.8 
 
 
3.1.3. Evaluation of bioactivity of a dry coated peptide formulation 
To determine whether MN coating excipient (i.e. PVA 2000) or the dry coating processes affected 
the bioactivity of the m31 peptide (lyophilised powder), both the pure m31 (mimotope control) and 
the coated m31 peptide (recovered after MN coating) were cultured with splenocytes from BDC2.5-
TCR-Tg mice (Fig.2). The bioactivity of m31 was determined by IFNγ release from BDC2.5 T cThere 
was no significant difference in the IFNγ production stimulated by control and coated m31 peptide 
at all studied concentrations (Fig.2). The negative control (Blank F), i.e. PVA 2000 solution alone, 
did not stimulate BDC2.5 splenocytes. 
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Fig 2.  Effect of MN coating on peptide bioactivity. The bioactivity of m31 peptide after formulating and 
subsequent dry coating was compared to the pure unaltered m31 peptide (lyophilised powder). Three 
concentrations of m31 peptide (10, 1 and 0.1 ng/ml) were tested. Stimulation of the splenocytes by the peptide 
was determined by measuring IFNγ levels. SP=splenocytes alone. Blank F=blank formulation without adding 
m31 peptide. N=3, Mean±SD. Unpaired two-tailed t-test; ns p>0.05. 
 
3.2. Understanding and optimising parameters that affect intradermal delivery of MN coated 
peptides 
 
3.2.1. The influence of the MN surface morphology on MN coating and delivery of the peptide 
formulation 
The surface morphology (roughness) of the MNs was modified by electropolishing (Fig. 3A). Visual 
observations of skin treated with m31-5TAMRA coated MNs indicated that unpolished MNs delivered 
less peptide than their electropolished counterparts (Fig.3B).  This was confirmed quantitatively 
using UV-vis spectrometry (Fig.3C), where 59.9±6.7 % of the coated dose was delivered using 
electropolished 500µm MNs compared to 2.0±1.0 % from their unpolished equivalents. 
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Fig.3.  Effect of MN surface morphology/roughness on m31-5TAMRA delivery efficiency.  A. SEM image 
of MN tip before (left) and after electropolishing (right). B. Images show MN array penetration and m31-
5TAMRA (pink) release into human skin explants after a 10-minute application. MNs with different surface 
properties were coated with the same mass of peptide (10µg) and applied to the human skin explant for 10 
minutes.  The penetration images were visualised using a stereoscopic microscope and processed with 
ImageJ software. C. Effect of MN surface morphology/roughness on delivery efficiency in human skin explants. 
m31-5TAMRA was delivered using 500µm (30 needles) MNs with or without electropolishing. N=3. Mean±SD. 
One-way ANOVA with Tukey’s post test. **p<0.01, ***p<0.001.  
 
3.2.2. Characterising MN coating thickness 
 
In order to better understand the distribution and thickness of the peptide formulation on the MN 
surface the coated MNs were imaged using SEM (Fig.4). Figure 4 shows that uncoated 
electropolished MNs have a smooth surface (Fig.4A) and an average needle length of 470.2 ± 
13.4µm (Fig.4B). The optimised coating formulation and manual coating technique coated the MNs 
relatively reproducibly (Fig.4). The method ensured that the coating was focused on the upper 
portion of the MN i.e. 339.1±16.3µm (2.2µg/needle), 312.2±10.2µm (0.73µg/needle) and 
309.8±19.6µm (0.37µg/needle) from the needle tip (Fig.4B). When the mass of the coated 
formulation was increased, the MN coating thickness increased whilst the distribution of the coating 
became less uniform i.e. it became concentrated in the central region of the needle (Fig.4 A, Fig.5, 
and Fig.6). This retained the tip sharpness. However, increasing the MN coating volume caused 
cracking of the dried film (Fig.4A; 2.2 and 0.73µg/needle). This was not observed on the thinly coated 
needles (Fig.4A; 0.37µg/needle). Nevertheless, the integrity of the coating remained intact during 
handling and microscopy of all of the coated MN arrays. 
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Fig.4. Coating distribution. A. SEM images of MNs coated with different coating doses. 10µg peptide and 
1µg PVA were coated onto 5, 15 or 30 needles, producing concentrations of 0.37µg/needle, 0.73µg/needle 
and 2.2µg/needle. Uncoated and coated MNs were imaged at x27 and x230 magnifications. Scale bar: 
x27=1000µm, x230=100µm. B. Needle length and coating length. Coating length was measured from needle 
tip to the central coating base line. n≥5. One way ANOVA with Tukey post test, ns=p>0.05, *p<0.05. 
 
The characteristics of the peptide coating were further analysed using a Zeta 3D optical profiler 
(Fig.5 and Fig.6), where coating thickness was analysed as a single longitudinal section (Fig.5) and 
in 10 latitudinal sections (Fig.6) taken from the microneedle tip to a position 120µm from the 
microneedle tip. Limited to the field of view of the instrument, the coating thickness was only 
measured on the upper 120µm of the MN. The height of the uncoated needle surface is evenly 
distributed across the 10 lines of latitude (Fig.6 A) and no change in surface height is observed along 
the longitude (Fig.5 A). Therefore the topography of uncoated microneedle surfaces is flat. When 30 
individual needles were coated (notionally 0.37µg/needle) adhesion of the liquid formulation to the 
needle surface resulted in a fairly consistent coating thickness, changing by 1.1µm from the first 
(3.6±0.1µm) to the tenth (4.7±0.2µm) latitudinal cross section (Fig.6 B&E), which was also reflected 
in a near flat longitudinal cross section (Fig.5 B). When the formulation was coated over 15 individual 
needles (notionally 0.73µg/needle) the coating thickness varied from 0.10±0.08µm at 30µm from the 
MN tip to 4.20±0.122µm at a 120µm distance from the needle tip, a difference of 4.10µm (Fig.5 C, 
Fig.6 C&E). Latitude measurements of the thickest coating (5 needles i.e. theoretically 2.2µg of 
material per needle) indicated that the thickness of the coating changed from 1.09±0.50µm at the 
needle tip to 16.8±0.244µm at 120µm from the needle tip (Fig.6 D&E). This difference of 15.71µm 
was confirmed in the longitude gradient measurements (Fig.5 D).  
 
Coating thickness also influenced the geometry of the coated MN. In the case of the thickest coating 
(2.2µg/needle), the coated MN assumed a more conical shape, as shown by the slope on the 
longitudinal thickness plot and the bell-shaped curves for latitudinal section plots (Fig 6. D). In the 
case of thinner coatings (both 0.73 and 0.37µg/needle), the slope of the longitudinal plots was less 
pronounced (note, the Y-axis ‘thickness’ scale was reduced when compared against the thickest 
coating plot) and the latitudinal cross section plots were generally flat (Fig.5 B&C). The cracks in the 
coating observed under SEM were also observed using the Zeta 3D profiler (Fig.5 D) and were 
evidenced by marked drops in surface height on the longitudinal thickness plot in the case of 2.2 
µg/needle (Fig.5D; indicated by red arrows). 
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Fig.5. Longitudinal 3D optical profiling of the coating thickness of WE14-5TAMRA peptide. Change to 
the surface height was measured along the longitudinal axis of the needle, i.e. from the tip to the central region. 
Representative images and measurement of uncoated needle (A) and needles coated with 10µg peptide and 
1µg PVA 2000 distributed over 30 (B), 15 (C) and 5 (D) needles producing concentrations of 0.37µg/needle 
(B), 0.73µg/needle (C) and 2.2µg/needle (D). 
 
A.
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Fig.6. Latitudinal 3D optical profiling of the coating thickness of WE14-5TAMRA peptide. Changes to 
the surface height were measured at 10 different latitudinal locations from the MN tip to the central region. 
Representative images and measurement of uncoated needle (A) and needles coated with 10µg peptide and 
1 µg PVA 2000 distributed over 30 (B), 15 (C) and 5 (D) needles producing concentrations of 0.37µg/needle 
(B), 0.73µg/needle (C) and 2.2µg/needle (D); E. Coating thickness of WE14-5TAMRA over the first 120µm 
from the needle tip for the 5, 15 and 30 needle samples producing mass loading of 0.37µg/needle, 
0.73µg/needle and 2.2µg/needle. n=3. 
 
 
 
3.2.3. Comparing the influence of coating thickness and peptide hydrophobicity on delivery 
efficiency in human and mouse skin 
 
The delivery efficiency from coated MNs was compared in two skin models i.e. human skin explant 
and murine skin. For the hydrophilic peptide WE14-5TAMRA, the delivery efficiency from a 30 needle 
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MN array in the human skin explant was 90.4±1.9 %, whilst delivery efficiency in mouse skin was 
60±6.6 % (Fig.7A, Table 5). For the hydrophobic peptide m31-5TAMRA, delivery efficiency from 30 
MNs was reduced although still significantly higher in the human skin explant (58.9±3.2 %) than 
mouse skin (19.5±4.7 %) (Fig.7B, Table 5). This observation also translated to the thicker MN 
coatings, i.e. coating distributed over 15 or 5 needles (Fig.7A&B, Table 5). 
 
The effect of coating thickness on delivery efficiency was also evaluated. For the hydrophilic peptide, 
WE14-5TAMRA, there was no difference in the delivery efficiency between 30 (90.4±1.9 %) and 15 
(89.04±2.26 %) MNs when applied to human skin, whilst a significantly lower delivery efficiency was 
observed when using the thicker coating i.e. over 5 MNs (65.5±7.7 %) (Fig.7A, Table 5). In mouse 
skin, the delivery efficiency of WE14-5TAMRA also decreased significantly when coating thickness 
increased from 0.37µg/needle (30 MNs coated) to 2.2µg/needle (5 MNs coated) (Fig.7A, Table 5). 
For the hydrophobic peptide, m31-5TAMRA, there was no significant difference in the delivery 
efficiency when the coating was distributed over 30 MNs or 15 MNs, either in the human skin explant 
(58.9±3.2 % vs 50.6±8.0 %) or mouse skin (19.5±4.7 % vs 16.2±3.5 %) (Fig.7B, Table 5). However, 
when the dose was distributed over 5 needles i.e. thicker MN coatings, there was a significant 
reduction in the delivery efficiency in both human skin (38.6±1.7 %) and mouse skin (5.9±3.6 %) 
(Fig.7B, Table 5). 
 
The intrinsic hydrophobicity of the peptide also influenced delivery efficiency when other parameters 
i.e. skin model and coating thickness, remained constant. Data in Fig.7C, relating to the use of 30 
MNs for peptide delivery into the human skin explant, suggests a significant increase in delivery 
efficiency from the MN with an increasing aqueous solubility of the peptide i.e. insulin B9-23 
(46.5±5.0 %) < m31 (58.9 ±3.2 %) < WE14 (90.4±1.9 %). Distribution of the m31 and WE14 peptides 
also differed in human skin. Whilst m31 peptide was delivered proximal to the microchannel created 
by the MN devices, WE14 peptide was more widely distributed in the epidermis and dermis following 
application of the coated MN to human skin (Fig.7D). 
 
 
 
Table 5. Delivery efficiency of WE14-5TAMRA and m31-5TAMRA in mouse skin and human skin 
explant. Data presented as Mean±SD % H=human skin explant, M=mouse skin 
Needle 
number 
Coating 
thickness 
µg/needle 
Skin 
Model 
Peptides 
WE14-5TAMRA  m31-5TAMRA 
30  0.37 
H  90.38±1.94 %  58.9±3.2 % 
M  60.0±3.9 %  19.5±4.7 % 
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15  0.73 
H  89.04±2.26 %  50.6±8.0 % 
M  44.8±8.8 %  16.2±3.5 % 
5  2.2 
H  65.48±7.66 %  38.6±1.7 % 
M  23.5±3.4 %  5.9±3.6 % 
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Fig.7. Comparing the influence of coating thickness and peptide hydrophobicity on delivery efficiency 
in human and murine skin. Electropolished MNs with different needle numbers (5, 10 or 30) were coated 
with 10µg of peptide-5TAMRA.  Delivery efficiency of m31-5TAMRA was quantified after 10 minutes 
application either in human skin explant or in mouse skin. A. Effect of skin derivation and coating thickness on 
delivery efficiency of WE14-5TAMRA. B. Effect of skin derivation and coating thickness on delivery efficiency 
of m31-5TAMRA C. Effect of peptide hydrophobicity on delivery efficiency in human skin explants using 
electropolished 500µm MNs.  The same mass (10µg) of hydrophilic peptide, WE14, and hydrophobic peptide 
(m31 and proinsulin B9-23) was coated and delivered to human skin explants using 3 arrays of ten 500µm 
long electropolished MNs.  Delivery efficiency was then calculated after MN application. Statistics for Fig.7A, 
B and C: n≥3. Mean±SD, one way ANOVA with Tukey post test,  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
D. Distribution of peptide-5TAMRA in human skin explant. Human skin explant was treated with 30 MNs coated 
with WE14-5TAMRA or m31-5TAMRA. Scale bar=200µm. 
 
4. Discussion 
 
4.1. Developing a coating formulation for hydrophobic peptides 
Several formulations have been developed previously for coating MNs including a coating 
formulation developed at GeorgiaTech, which was used to coat peptide, vaccine, salmon calcitonin, 
bovine serum albumin and plasmid DNA [13, 15, 21, 22, 25]. This aqueous formulation typically 
contains 1% (w/v) carboxymethylcellulose sodium salt, 0.5 % (w/v) Lutrol F-68 NF and 15 % (w/v) 
trehalose in PBS.  If a poorly soluble hydrophobic peptide were able to dissolve in this coating 
formulation at a concentration of 1mg/ml, i.e. 0.1 % (w/v), then the API to excipient ratio would be 
1:165, i.e. 1650µg of excipient would be co-coated with the target dose of 10µg of peptide. The mass 
of excipients required in this scenario would therefore be prohibitive for some MN applications. 
Coating formulations designed for more hydrophobic molecules have also been reported, although 
these studies are more limited.  Gill et al. utilised organic solvents such as ethanol and acetonitrile 
to dissolve hydrophobic compounds for MN coating [15]. One disadvantage of these solvents is their 
high volatility. This makes it difficult to control the coating formulation concentration, which can 
influence the accuracy and repeatability of coating. The authors also investigated a coating 
formulation for hydrophobic molecules using a molten polymer, polyethylene glycol (Molecular 
Weight 1500).  However, the high process temperature (45˚C) and the low drug loading capacity 
(0.01%w/v) make this impractical for biologics. The present study describes a coating formulation 
suitable for three hydrophobic peptides, WE14, m31 and proinsulin B9-23 which have potential 
clinical applications for ASI for T1D.   
 
A number of critical parameters were identified as key to the suitability of a MN coating formulation 
for therapeutic hydrophobic peptides:  (i) a predominantly aqueous system that maintains peptide 
bioactivity, (ii) co-solvents to be, at least partially, miscible with water and have a similar vaporisation 
rate, in order to prevent phase separation, (iii) formulation evaporation at room temperature and 
atmospheric pressure to allow peptide coating and MN drying using ambient conditions, (iv) 
excipients that do not stimulate a pro-inflammatory immune response, (v) a minimal excipient mass 
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to maximise the peptide loading capacity of the MN, without reducing tip sharpness, (vi) peptide 
solubility of ≥ 10mg/ml to minimise the volume of coating formulation required and hence the coating 
time, and (vii) formulation stability at -80 ˚C to enable long term storage of peptide with maintained 
bioactivity, (vii) lack of toxicity toward the targeted responding cells. 
 
The first step to develop a formulation to meet these criteria was to use a pH modifier to increase 
peptide polarity and solubility. Acetic acid is a weak organic acid that has been widely used to 
dissolve hydrophobic peptides [26] and insulin [27]. A 2M aqueous acetic acid solution can be used 
to dissolve WE14, a peptide with 43% hydrophobic groups, at a concentration of 25mg/ml.  However, 
for other hydrophobic peptides such as m31, a basic peptide with 60% hydrophobic groups, and 
proinsulin B9-23, a neutral peptide containing 40% hydrophobic groups, increasing ionisation alone 
was not sufficient to ensure dissolution at the desired concentration and therefore a co-solvent was 
also included. DMSO (dimethyl sulfoxide) is a commonly used solvent for dissolving hydrophobic 
peptides. However the formation of sulphoxide or disulphide bonds with amino acids, such as 
cysteine, methionine and tryptophan residues [28] make it inappropriate for the methionine and 
tryptophan containing WE14 and m31. Alcohols were considered to be more appropriate co-solvents 
with a focus on a carbon chain length of below 5 to ensure that the hydrophilic influence of the 
hydroxyl group was not compromised by the hydrophobic effects of the hydrocarbon chain. Two 
alcohols were selected, tert-butanol and tert-amyl alcohol. Tert-butanol was unable to dissolve 
peptide at the desired concentration, even with the addition of acetic acid solution. However, tert-
amyl alcohol was able to dissolve m31 at a concentration of 50mg/ml and proinsulin B9-23 at 
25mg/ml. As tert-amyl alcohol is known to be only partially miscible with water it was necessary to 
test the miscibility of the ternary system i.e. water, acetic acid and tert-amyl alcohol.  The ternary 
system was able to form a uniform mixture when the respective molar ratios fell beneath the solubility 
ternary phase curve [29] and therefore tert-amyl alcohol proved to be an appropriate co-solvent in 
the coating formulation.  
 
Five additional excipients that were able to modify the surface tension of the coating formulation 
were also assessed to optimise adhesion of the coating to the MN whilst enabling de-coating in situ. 
The addition of the dispersant PVA 2000 was shown to provide both effective MN coating and 
effective delivery of the coated formulation into human skin, possibly because PVA 2000 dissolves 
more rapidly in an aqueous environment than other excipients, resulting in rapid release of the 
peptide into the skin. Results of the splenocyte stimulation experiment (IFNγ readout) indicated that 
the concentration of PVA 2000 used in the coating formulation did not trigger a non-specific 
inflammatory response. This is an important requirement when the goal is to induce immune 
tolerance rather than activation [18]. PVA 2000 was therefore included as an excipient (stabiliser, 
viscosity enhancer, dispersant) in the coating formulation. During formulation of the coating solution 
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the tert-amyl alcohol, acetic acid solution and PVA solution were added sequentially to the peptide 
to ensure complete peptide dissolution. Deviation from this resulted in insufficient dissolution of 
hydrophobic peptides. This is possibly because tert-amyl alcohol acts as dispersant increasing the 
contact area with the acetic acid, which then protonates the free peptide and increases its aqueous 
solubility.  
 
This novel combination of excipients enabled coating of even the most hydrophobic peptides without 
a significant and detrimental effect on the MN dosing capacity i.e. only 1µg of excipient was coated 
onto the MN array for every 10µg peptide. This excipient:drug ratio is considerably lower than ratios 
reported in other studies using hydrophobic compounds [15] or peptides [21]. This is accompanied 
by preserved bioactivity of the peptide, as illustrated by the stimulation of IFNγ production by the 
m31 peptide, also shown in a previous publication which used WE14 and EBVP1 peptides [18], and 
a formulation that would potentially be considered biocompatible. Evaporation of the volatile co-
solvents and the use of an approved pharmaceutical excipient, PVA, which is available as a clinical 
grade material, would allow the coating formulation to potentially be translated to clinical use. This 
stated formulation therefore provides encouragement to those developing dry coated MN systems 
for the clinical delivery of hydrophobic biologics. 
 
4.2. Optimising delivery from coated stainless steel MNs 
Effective localised delivery of a therapeutic cargo from a coated MN that has been inserted into 
human skin relies upon release of the peptide from the MN surface. Subsequent peptide dissolution 
and diffusion then controls local pharmacokinetics. The combined effect of these processes 
contributes to the final delivered dose. Stainless steel MN arrays were electropolished in-house to 
determine the influence of the gross MN surface morphology on peptide release in situ. 
Electropolishing reduced MN dimensions by approximately 12.5% and therefore, during the design 
of electropolished MN delivery systems, this reduction in needle height must be accounted for. Whilst 
the m31-5TAMRA peptide was not released from unpolished MNs in the local skin environment, 
electropolished MNs released approximately 60% of the peptide from the MN surface. Therefore, 
whilst the reduced surface roughness of the electropolished MN maintains efficient coating, it also 
minimises adherence of the coating material to the needle surface and thus facilitates more effective 
delivery of the payload on insertion/removal of the MN. The surface features of MNs, at the micron 
scale, may therefore be important parameters in the design of coated MN drug delivery systems.  
 
The MN coating thickness was analysed by SEM and a Zeta 3D optical profiler. Observations using 
SEM suggested that the manual coating process is able to create reproducible coating thicknesses 
with a very small standard deviation. The coating length covered 65-70% of the needle length from 
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the tip and the base of the MN remained uncoated. When 10µg of WE14-5TAMRA was distributed 
over 5 needles (2.2µg/needle) the coating length was significantly greater than thinner coatings (0.37 
and 0.73µg/needle). Previous studies indicate that the full length of the MN is not inserted into the 
skin (Sup Fig1 and [30, 31]) and therefore a difference in the length of the coating becomes more 
important if a proportion of the coated area of MN is not inserted into the tissue. In the development 
of coated MNs delivery systems for clinical use it will therefore be important to develop a coating 
formulation, and process, that ensures reproducible coating of the needle shaft to a length that is 
appropriate for the insertion characteristics of the specific MN device and/or applicator system.  
 
On further inspection, SEM images revealed cracks in the dried formulation on the more thickly 
coated MNs (0.73 and 2.2 µg/needle) but not on those with the thinnest coating (0.37µg/needle). 
The Zeta 3D profiler also identified such cracks, confirming that these features are not simply a result 
of sample processing for SEM, but rather a result of volume contraction during the evaporative drying 
process under ambient conditions. Data from delivery efficiency experiments indicate that surface 
cracks do not significantly affect delivery and no obvious deleterious effects were witnessed during 
laboratory handling. However, the integrity of the dry-coated formulation should be considered in the 
handling, transport and storage of dry coated MNs when translating the technology to mass and 
widespread clinical utility. The Zeta 3D profiler was also used to measure the thickness of the MN 
coating. The tips of needles were shown to remain sharp in all three cases, with only slight changes 
(1-4 µm) to the width of the uncoated needle tip. Where 2.2µg of coating material is loaded per 
needle, the thickness of the coating film increases significantly at a distance of 40µm from the needle 
tip. The change in coating thickness was less dramatic when the coating was distributed over 15 
needles (0.73µg/needle). A more uniform coating thickness was achieved when the 11µg of coated 
material (10µg peptide plus 1µg excipient) was distributed over 30 individual MNs. Therefore, when 
thinner coatings are applied, surface adhesion results in even distribution of the coated material. 
However, when thicker coatings are employed surface tension and cohesive effects draw the coating 
formulation towards the centre of the needle and way from the needle tip resulting in less coating at 
the very tip of the needle and accumulation of the coating towards the centre of the needle. This is 
clearly evident when 2.2µg of material is loaded per needle as both the longitudinal and latitudinal 
measurements show that the coating thickness rapidly overtakes the thickness of the thinnest 
coating even towards the very tip of the needle. Whilst the thickness of the 0.73µg/needle coating 
does not overtake the (consistent) thickness of the 0.37µg/needle coating up to 120µm from the tip 
of the needle, the increasing trajectory of coating thickness suggests that it will towards the centre 
of the needle.  Controlling and validating the coating of MNs will became increasingly important as 
MN devices move from the laboratory bench to clinical trials and industrial manufacture. In this study, 
the Zeta 3D profiler has proved to be a useful tool for analysing transparent or semi-transparent MN 
coatings and could be used as a rapid screening quality control tool.  
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Differences in the uniformity of coatings may not only be a process control issue but may also 
translate to differences in skin delivery efficiency, causing heterogeneity in the dissolution of the 
coating from a MN and into the surrounding skin environment. Uniform coating is likely to facilitate 
more uniform release and dissolution from the MN surface, thus improving delivery efficiency and 
consistency. This may be particularly important when materials of reduced aqueous solubility are 
coated.  Cormier et al., 2004 [2] demonstrated that an increased coating thickness resulted in 
reduced delivery efficiency when an increased mass of desmopressin was coated on steel MNs. In 
this study we show that when 10µg of a relatively hydrophobic peptide, m31-TAMRA, was distributed 
over 15 needles, rather than just 5 needles, resulting in a thinner coating, the delivery efficiency is 
dramatically increased. Delivery efficiency was further increased when the m31-TAMRA formulation 
was coated over 30 needles although this was not statistically significant.  
 
Peptide hydrophobicity may be expected to influence delivery efficiency when coated MNs are 
inserted into skin. This study used excised human skin to confirm that more hydrophilic peptides 
(WE14) can be delivered more efficiently than more hydrophobic peptides (m31 and proinsulin B9-
23). Traditional topical transdermal drug delivery tends to favour drugs that are hydrophobic, 
however the electropolished coated MNs used in this study circumvents the lipophilic SC barrier and 
introduces the therapeutic peptide to a depth of 300-400µm below the skin surface (Sup Fig.1). This 
targets the payload to the viable epidermis and papillary dermis. The dermis is an aqueous region 
of tissue, consisting of 70% water [32] and therefore improved delivery of a more hydrophilic peptide 
may be facilitated by more rapid and extensive dissolution in the local tissue.  
 
Disease models are required to test the biological functionality of most novel pharmaceuticals and 
therefore delivery efficiency from the coated MN was also examined in mouse skin. There are 
notable biomechanical, architectural and biological differences between human and mouse skin [33-
35] and these differences translated to differences in the delivery efficiency witnessed in this study 
for both the hydrophilic WE14 peptide and the more hydrophobic m31 peptide. In all of the studied 
conditions, delivery efficiency in mouse skin was significantly less than in human skin.  We postulate 
that this reduced delivery efficiency is a direct result of differences in the dimensions of the tissue 
and the water available for dissolution. The thickness of human epidermis is typically 60-100µm 
compared to 20µm in mouse skin ([36, 37] and sup Fig.2), and the human dermis is 1.6-2.6mm [38] 
compared to just 200-300µm in the mouse. The absolute water content available for dissolution of 
the MN coating is therefore considerably less in the mouse model and results in a significantly 
reduced delivery efficiency compared to its human counterpart. With this in mind, when testing 
coated MN devices, it is important to consider both the source of the skin and its level of hydration.  
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Although the dermis is a hydrated aqueous environment, the free water available for dissolution of 
the MN coating in the tissue proximal to the inserted needle is finite [39]. This, together with the 
previously discussed coating thickness and aqueous solubility of the peptide, determines the 
saturation threshold for the MN delivered peptide. Therefore the most hydrophilic peptide tested, 
(WE14), dissolves readily in human skin tissue with no significant difference in delivery to human 
skin efficiency when the dose is coated over 30 needles compared to 15 needles. It is only when the 
thickness is significantly increased, with the drug coated over just 5 needles, that delivery efficiency 
in human skin is significantly reduced. This has also been witnessed for other water-soluble drugs 
delivered by coated MNs. For example, low dose and high dose (1µg or 7µg) bevacizumab, coated 
MNs can achieve similar delivery efficiency between 40%-50%, albeit in an ocular study [40]. Similar 
observations were also made for human growth hormone coated MNs delivered into skin [12]. For 
less soluble drugs, such as the m31 peptide, there is likely to be local saturation. This may 
necessitate extended insertion times to enable complete dissolution of the MN coating. However, 
this study has shown that it is possible to negate this saturation effect by distributing the dose over 
a greater number of MNs, thus enabling thinner MN coatings and smaller localised doses of drugs 
that are targeted to a wider area of the tissue. The number of individual MNs on an array is a 
modifiable parameter that can therefore be optimised for the specific drug to facilitate efficient and 
rapid drug release whilst maintaining the total delivered dose. However, it should be noted that 
changes to MN numbers and/or arrangements to accommodate different active pharmaceutical 
ingredients is also likely to influence the penetration performance of the device and this must be 
considered by MN developers during the pre-clinical phase. 
 
5. Conclusion 
In conclusion, a novel MN coating formulation system was developed for coating peptides with a 
spectrum of aqueous solubility. This formulation contains ternary co-solvents, water, 2-methyl-2-
butanol (amyl-alcohol) and acetic acid, and PVA 2000. No loss of bioactivity was detected when 
peptides were formulated using this coating solution and the peptides could be reproducibly 
delivered to skin from the surface of electropolished MNs. 
 
The factors influencing the cutaneous delivery efficiency of peptides from coated MNs include: 1) 
choice of excipient, 2) intrinsic hydrophobic property of the chosen peptide, 3) surface 
morphology/roughness of the MNs, 4) the coating thickness and 5) the species of skin model. This 
provides useful guidance in identifying critical attributes of the formulation, coating and delivery 
process that confer reproducible and effective delivery of coated MN formulations and contributes to 
the requirements of the regulators appraising these devices. 
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We propose a general formula showing the relationship between some of the critical factors that 
influence the delivery efficiency of coated MNs:  
 
�� ∝  
1
������ℎ�������
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1
����ℎ����
,
�
����
, � 
 
DE = Delivery efficiency 
∝ = Proportional to 
Hydrophobicity = Hydrophobicity of coated API 
Roughness = MN surface roughness 
Mass = Total mass coated onto MNs 
N = Total number of MNs 
H = Hydration state of the skin 
 
Whilst we acknowledge that formulation excipients also play an important role in the delivery 
efficiency from a coated MN, in this study only a small proportion of excipient was employed and 
therefore its impact on delivery efficiency was minimised.  
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Supplementary Figures: 
 
Fig 1. Penetration depth of 500µm length MNs in split-thickness human skin explant. 
 
 
Fig 2. H&E staining of a human and NOD mouse skin section. 
 
 
